TABLE 2.
ADHERENCE TO EVIDENCE-BASED GUIDELINES: PAIN MANAGEMENT
| Adherence | |||
|---|---|---|---|
| Management Quality Indicator | % | n | Total Chartsa |
| Resident is on acetaminophen. | 93 | 262 | 283 |
|
Resident is on opioid medications for moderate to severe pain despite optimized acetaminophen; no or mild pain (treatment is effective). |
15 | 37 | 245 |
|
Resident is not prescribed propoxyphene or meperidine. |
99 | 28 | 285 |
|
Resident is on round the clock treatment for constant/multiple episodes of daily pain; no or mild pain (treatment is effective). |
25 | 45 | 181 |
|
Resident is not prescribed nonsteroidal anti- inflammatory drugs for inappropriate reason. |
93 | 264 | 285 |
|
Resident is on topical agent or other drug for neuropathic pain. |
23 | 33 | 141 |
|
Treatment given for persistent or severe side effects of drugs.b |
9 | 5 | 58 |
| Nondrug therapies used. | 11 | 30 | 285 |
Note. Percentages represent adherence to evidence-based guidelines at the highest level.
a
Denominator for each item excludes all charts for which the item was marked as not applicable.
b
Treatment for persistent or severe side effects may be overestimated due to low rates of assessment and/or documentation of side effects.